NESS ZIONA, Israel (March 23, 2015) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the European Commission, acting on the…
Experienced industry executive enhances medical knowledge and capability
Posts Record Revenue for the Fourth Quarter and Generates Net Profit
Conference call begins today at 8:30 a.m. Eastern time
Conference call to report Fourth Quarter and Year End 2014 financial results scheduled for February 11, 2015
Majority of patients who continued treatment with AAT maintained capability of insulin secretion and attained glycemic targets with HbA1C level below 7.5% for more than 2 years after diagnosis of type 1 diabetes
Expects to report results from its Anti-Rabies Immunoglobulin U.S. Phase II/III clinical trial in the first half of 2015
Results support publication of pre-clinical data in Blood in September
Kamada announces financial results for the three and nine months ended September 30, 2014 and affirms 2014 revenue guidance.
Kamada management will host an investment community conference call on Wednesday, November 12, 2014 at 8:30 a.m. Eastern time to discuss these results and answer questions.
Orphan drug designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process.